Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference scheduled for April 7-10, 2025. The company's management team will deliver a presentation on April 9, 2025, from 1:30 - 2:10 pm ET.

The presentation will feature key executives including CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman, and CAO Mallory Morales. They will discuss Immuneering's pipeline, platform, and business strategy. The event will include both a company presentation and one-on-one investor meetings.

Interested parties can access the live webcast and archived recording through the Investor Relations section of Immuneering's website under Events & Presentations.

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Igor Matushansky, Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer, Secretary and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Company Presentation and 1x1 Investor Meetings

Date/Time: April 9 from 1:30 – 2:10 pm ET

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

Media Contact: 
Jenna Urban 
jurban@cglife.com 

Investor Contact: 
Laurence Watts 
619-916-7620 
laurence@newstreetir.com 

FAQ

When is Immuneering (IMRX) presenting at the Needham Healthcare Conference 2025?

Immuneering will present on April 9, 2025, from 1:30 to 2:10 pm ET at the 24th Annual Needham Virtual Healthcare Conference.

Which executives from IMRX will participate in the Needham Healthcare Conference?

The presenting team includes CEO Ben Zeskind, CSO Brett Hall, CMO Igor Matushansky, CBO Harold Brakewood, CLO Michael Bookman, and CAO Mallory Morales.

How can investors watch Immuneering's (IMRX) Needham Conference presentation?

The presentation will be available via live webcast and archived recording in the Investor Relations section of Immuneering's website under Events & Presentations.

What topics will IMRX cover during the Needham Healthcare Conference presentation?

The presentation will cover Immuneering's pipeline, platform, and business strategy in oncology drug development.